RA
SPRB

Rosalind Advisors’s Spruce Biosciences SPRB Stock Holding History

Rosalind Advisors’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Buy
+20,000
New +$1.12M 0.4% 27
2024
Q3 		– Sell
-20,112
Closed -$781K – 43
2024
Q2 		$781K Hold
20,112
– – 0.6% 30
2024
Q1 		$1.19M Sell
20,112
-1,040
-5% -$264K 1.11% 26
2023
Q4 		$4.65M Buy
+21,152
New +$2.44M 3.83% 13

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

Rosalind Advisors's SPRB Position: Q2 2026 in Review

Rosalind Advisors opened a new position in Spruce Biosciences (SPRB) in Q2 2026: 20,000 shares worth $1.08M. The stake represents 0.4% of the portfolio and ranks #27 among its holdings. This is a return to the name: Rosalind Advisors previously reported a position in SPRB as recently as Q2 2024.

Rosalind Advisors first reported a position in SPRB in Q4 2023 and has held it in 4 quarters since. The position peaked at $4.65M in Q4 2023. 63 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • Rosalind Advisors held 20,000 shares of Spruce Biosciences worth $1.08M as of Q2 2026.
  • Spruce Biosciences was a new Rosalind Advisors position in Q2 2026.
  • Spruce Biosciences made up 0.4% of Rosalind Advisors's portfolio in Q2 2026, its #27 holding.
  • Rosalind Advisors first reported a position in Spruce Biosciences in Q4 2023 and has held it in 4 quarters since.
  • Rosalind Advisors's Spruce Biosciences position peaked at $4.65M in Q4 2023.
  • 63 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on Rosalind Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.